HLN

Rating neutralTentativeAI Memo

Haleon

As of 2026-08-02/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

neutral

Confidence

low

Horizon

—

Key catalyst

H1 2026 earnings beat with unchanged guidance • 2026-07-30

Expected move: +13%

Biggest risk

Organic growth remains below Haleon's 4%-6% medium-term ambition. Respiratory Health declined 4.7% in H1, Europe remains weak, and the H2 outlook depends on execution, seasonal recovery, and absorption of higher freight costs.

Invalidation

Break below $8 or thesis failure.

What would change my mind?

The earnings print combined an operating-profit and EPS beat with unchanged FY guidance. North America improved to 3.1% Q2 growth, Oral Health remained strong, and productivity is expanding margins while funding brand investment.

Research note

Recommendation

neutral

Confidence

low

As of

2026-08-02

Base target

$11

p=50%

Bull target

$13

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 execution checkpoint
Oral Health innovation and share gains
Supply-chain productivity and capacity expansion

BearKey bullets

Europe is facing low-single-digit category declines, while Middle East weakness and freight inflation may pressure H2 results.
H1 organic growth of 2.6% is below the 4%-6% medium-term ambition.
Peer comparability and post-print analyst revision evidence are weak, limiting confidence in valuation conclusions.

WatchKey bullets

H1 2026 earnings beat with unchanged guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

Asset

Equity

Trigger

Base case: $11 (p=50%)

Bull/Bear spread: +27% / -16%

Vs latest close: Bull +27% · Base +13% · Bear -16%

Scenario probabilities

Bull Target: $13 (p=25%)Base Target: $11 (p=50%)Bear Target: $8 (p=25%)

Commentary

Recent news tone is mixed-to-negative: Reuters reported that sales-growth concerns overshadowed the profit beat, while Haleon's official results showed stronger margins and EPS. No post-print analyst target, rating, estimate-revision, options, short-interest, or usable social data were available; confidence remains limited.

As of 2026-08-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 execution checkpoint
Oral Health innovation and share gains
Supply-chain productivity and capacity expansion

Scenarios

Bull Target (Scenario probability)

$13 / p=25% prob

Base Target (Scenario probability)

$11 / p=50% prob

Bear Target (Scenario probability)

$8 / p=25% prob

Price $10 as of 2026-07-31

Nearest Scenario: Base (∆ 13%)

Targets vs latest close: Bull +27% · Base +13% · Bear -16%

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-07-30
H1 2026 earnings beat with unchanged guidance
H1 revenue was £5,602m, organic growth was 2.6%, adjusted operating profit was £1,364m, and adjusted EPS was 10.3p. Haleon-hosted consensus was £5,593m revenue, £1,320m adjusted EBIT, and 10.0p EPS. FY guidance remained 3%-5% organic growth and high-single-digit adjusted operating-profit growth. [#PR-HLN-HY26-2026-07-30] [#EARNINGS-TRANSCRIPT-2026Q2]
Prob 88.00% • Move 3.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Q3 execution checkpoint
2026-10-29
The 29 October trading statement should test the expected H2 acceleration through North American shelf-reset and distribution gains, lower Middle East drag, and improving cold-and-flu comparisons. [#IR-HLN-EVENT-2026-10-29]
Prob 70% • Move 4% • Priced-in 35%

Long-term Catalysts

Months to a year

Oral Health innovation and share gains
2027-06-30
Oral Health delivered 7.3% organic H1 growth and 6.2% in Q2, led by Sensodyne, parodontax, and innovation such as Sensodyne Clinical Repair. Sustained execution could support recovery toward Haleon's 4%-6% medium-term growth ambition, but this remains execution-dependent. [#PR-HLN-HY26-2026-07-30]
Prob 62% • Move 8% • Priced-in 60%
Supply-chain productivity and capacity expansion
2027-08-02
H1 adjusted gross margin expanded 140 basis points, while Haleon targets £800m of gross supply-chain savings by 2030 and announced approximately £240m of manufacturing investment in China and India. Freight costs and execution are key gating factors. [#PR-HLN-HY26-2026-07-30]
Prob 65% • Move 10% • Priced-in 55%

Risks

Europe is facing low-single-digit category declines, while Middle East weakness and freight inflation may pressure H2 results.
H1 organic growth of 2.6% is below the 4%-6% medium-term ambition.
Peer comparability and post-print analyst revision evidence are weak, limiting confidence in valuation conclusions.
Respiratory Health declined 4.7% in H1 and 6.5% in Q2; management expects only a partial cold-and-flu recovery.
The unchanged FY outlook requires a second-half acceleration that has not yet been demonstrated.

Peers

Symbol	Summary
AMGN	Large-cap biopharma comparator supplied in the packet, but not a close consumer-health business-model peer; valuation comparison is low signal.
GILD	Large-cap healthcare comparator supplied in the packet, but its therapeutics exposure makes direct comparison with Haleon's branded consumer-health portfolio weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-08-02

AI Stock Memo: HLN - Haleon - RankAlpha